NRx Pharmaceuticals, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP; NRXPW) between June 1, 2021 and November 4, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 21, 2022.

If you purchased NRx securities and would like to join the action, please click “Join This Class Action,” above.

集体诉讼期:June 1, 2021 through November 4, 2021
If you purchased NRx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.


According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:

  • the ZYESAMI EUA Application contained insufficient data regarding the potential benefits and risks of ZYESAMI;
  • accordingly, the FDA was unlikely to approve the ZYESAMI EUA Application in its present form; and
  • as a result, the Company’s public statements were materially false and misleading at all relevant times.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.

公司名称: NRx Pharmaceuticals, Inc.
股票代号: NRXP
集体诉讼期: June 1, 2021 through November 4, 2021
法院: United States District Court for the District of Delaware


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。


Scroll to Top